The stock has a 36-month beta value of 1.98. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EBS is 51.92M, and at present, short sellers hold a 15.39% of that float. On July 09, 2025, the average trading volume of EBS was 1.26M shares.
EBS) stock’s latest price update
Emergent Biosolutions Inc (NYSE: EBS)’s stock price has plunge by 4.95%relation to previous closing price of $6.87. Nevertheless, the company has seen a 9.24% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-08 that GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.
EBS’s Market Performance
Emergent Biosolutions Inc (EBS) has seen a 9.24% rise in stock performance for the week, with a 8.75% gain in the past month and a 62.39% surge in the past quarter. The volatility ratio for the week is 6.78%, and the volatility levels for the past 30 days are at 6.02% for EBS. The simple moving average for the past 20 days is 9.05% for EBS’s stock, with a -6.05% simple moving average for the past 200 days.
Analysts’ Opinion of EBS
Many brokerage firms have already submitted their reports for EBS stocks, with H.C. Wainwright repeating the rating for EBS by listing it as a “Buy.” The predicted price for EBS in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on December 30, 2024 of the previous year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see EBS reach a price target of $16. The rating they have provided for EBS stocks is “Buy” according to the report published on August 22nd, 2024.
The Benchmark Company gave a rating of “Buy” to EBS, setting the target price at $5 in the report published on March 07th of the previous year.
EBS Trading at 15.80% from the 50-Day Moving Average
After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.25% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EBS starting from Katkin Keith, who sale 7,844 shares at the price of $6.30 back on May 23 ’25. After this action, Katkin Keith now owns 86,431 shares of Emergent Biosolutions Inc, valued at $49,417 using the latest closing price.
Stock Fundamentals for EBS
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.32 for the gross margin
The net margin for Emergent Biosolutions Inc stands at -0.14. The total capital return value is set at -0.04. Equity return is now at value -21.63, with -8.15 for asset returns.
Based on Emergent Biosolutions Inc (EBS), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at 0.17. The debt to equity ratio resting at 1.2. The interest coverage ratio of the stock is -0.88.
Currently, EBITDA for the company is 36.9 million with net debt to EBITDA at 4.86. When we switch over and look at the enterprise to sales, we see a ratio of 0.95. The receivables turnover for the company is 4.71for trailing twelve months and the total asset turnover is 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.32.
Conclusion
To sum up, Emergent Biosolutions Inc (EBS) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
